Premium
The continual reassessment method in cancer phase i clinical trials: A simulation study
Author(s) -
Chevret Sylvie
Publication year - 1993
Publication title -
statistics in medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.996
H-Index - 183
eISSN - 1097-0258
pISSN - 0277-6715
DOI - 10.1002/sim.4780121201
Subject(s) - flexibility (engineering) , computer science , sensitivity (control systems) , clinical trial , prior probability , phase (matter) , maximum tolerated dose , econometrics , medical physics , data mining , statistics , medicine , mathematics , artificial intelligence , bayesian probability , chemistry , organic chemistry , electronic engineering , engineering
In cancer studies, the aim of phase I clinical trials is to identify an appropriate dose for experimentation in phase II and III studies. The continual reassessment method (CRM) has been developed recently and presented as the method of choice in the design and analysis of such phase I studies. However, to implement the method, some methodological and practical considerations must be addressed. This paper examines, through a simulation study, the sensitivity of CRM both to the initial modelling of the dose‐toxicity relationship and the prior. It appears that the performance of CRM can be improved by using vague priors and initial tuning of the model to allow flexibility.